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Objectives: To characterize the utility of nitrotyrosine (NT) as a biomarker for arthritis and joint injury.
Design: Synovial ﬂuid, plasma, and urine from patients diagnosed with osteoarthritis (OA), rheumatoid
arthritis (RA), anterior cruciate ligament (ACL) injury, meniscus injury and pseudogout, and knee-healthy
volunteers were analyzed for concentrations of NT, nitrate and nitrite (NOx), matrix metalloproteinase
(MMP)-3, MMP-1, MMP-9, more than 40 chemokines and cytokines.
Results: In OA, plasma and synovial ﬂuid NT were increased versus healthy volunteers. Synovial ﬂuid to
plasma NT ratios were elevated in OA patients. Synovial ﬂuid from patients with ACL and meniscus injury
and pseudogout had increased levels of NT (P < 0.001). In these samples, NT levels signiﬁcantly corre-
lated with ARGS-aggrecan neoepitope generated by aggrecanase cleavage of aggrecan (P  0.001), cross-
linked C-telopeptides of type II collagen (P < 0.001), MMP-1 (P ¼ 0.008), and MMP-3 (P  0.001). In RA,
plasma NT decreased following 6 months of anti-tumor necrosis factor (TNF) treatment. For every 1.1%
change in log10 NT, there was a 1.0% change in the log10 disease activity scores (DAS28-3 CRP). Both
predicted and observed DAS28-3 CRP showed a robust linear relationship with NT. RA plasma NT
positively correlated with CRP, MMP-3 and interferon g-induced protein 10.
Conclusions: NT may serve as a useful biomarker for arthritis and joint injury. In RA, NT is highly
correlated with several biomarkers and clinical correlates of disease activity and responds to anti-TNF
therapy.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Increased nitric oxide synthase (NOS) activity has been linked to
joint injury and is associatedwith increased chondrocyte apoptosis,
increased matrix metalloproteinase (MMP) activity and decreased
extracellular matrix synthesis1. Osteoarthritis (OA) and rheumatoid
arthritis (RA) show increased tissue staining for both inducible
nitric oxide synthase (iNOS) and its downstream product,
nitrotyrosine (NT)1e6. NT is a stable marker resulting from the
generation of peroxynitrite, a powerful oxidant arising from theT.P. Misko, 141 Heatherwood
.
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Although diet is a source of nitrate in vivo and should be considered
when assessing this metabolite as a biomarker for NOS activity,
numerous studies have used nitrate and nitrite (NOx) as a measure
of NO production in arthritis7e12. Studies on RA showed increased
levels of plasma and synovial ﬂuid nitrite7e12, and synovial ﬂuid
NT13 but have not demonstrated a therapeutic response of these
biomarkers.
Recent work has shown increased nitrated type II collagen in
serum from patients with OA and RA14, although this measure is
speciﬁc to type II collagen and would not include synovial and other
joint tissue targets for peroxynitrite. A biomarker, such as NT that is
derived frommultiple nitratively modiﬁed joint proteins rather than
solely from type II collagen, may better reﬂect the extent of joint
pathology and provide a more robust response to therapeutic inter-
vention. In the present investigation, we therefore determined NT
and NOx in plasma, urine and synovial ﬂuid samples from patients
with joint injury, OA, pseudogout and RA, and related these levels to
arthritis biomarkers and clinical correlates of disease activity.ublished by Elsevier Ltd. All rights reserved.
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Human samples
For all human samples, the protocol and informed consent
documentations were reviewed and approved by Institutional
Review Board(s) and/or Independent Ethics Committee(s) at each
study center. Written informed consent was received from all
eligible patients before procedures were initiated. The procedures
followed were in accordance with the ethical standards of the
responsible committee on human experimentation (institutional
and national) and with the Helsinki Declaration of 1975, as revised
in 2000. Samples (plasma, synovial ﬂuid, and urine) were obtained
from the following cohorts.
Cohort 1: human plasma samples
Subjects with knee OA were all female and obese [body mass
index (BMI) 30] with symptomatic OA as evidenced by frequent
knee symptoms during the course of the year. These included pain,
aching or stiffness on most days of the month, along with the
frequent use of medication. Subjects with Kellgren and Lawrence
grades 2 or 3 of the signal knee (with either the same or less severe
OA or no OA of the contralateral knee) were included in this OA
cohort (n¼ 83). The control group (n¼ 92) had no evidence of knee
OA in either knee (i.e., Kellgren and Lawrence grade 0 diagnosed by
X-ray on anteroposterior view; infrequent knee pain, aching or
stiffness the year prior to the study; or infrequent use of medication
for treatment of knee pain).
Cohort 2: matched human OA plasma and urine samples
Matched plasma and urine samples were obtained from male
and female patients (n¼ 20) with painful knee OA, X-ray conﬁrmed
Kellgren and Lawrence grade 2 or 3, aged40 years and a BMI35.
Any evidence of inﬂammatory arthritis resulted in exclusion from
the study. Patients had no non-steroidal anti-inﬂammatory drug
use for 7 days prior to sample collection. Control subjects (n ¼ 20)
were age- and gender-matched with the OA group and were
conﬁrmed by radiography to have no evidence of OA in the knees,
hips or dominant hands.
Cohort 3: human synovial ﬂuid samples (OA, joint injury,
pseudogout, controls)
Because NT in plasma and urine could be derived from sources
outside OA joints, we analyzed synovial ﬂuid from OA and joint
injury [anterior cruciate ligament (ACL) and/or meniscus rupture]
patients who often develop OA following injury15. In addition,
because increased synovial ﬂuid levels of NT support a role for
peroxynitrite-mediated joint tissue injury in OA and ACL injury, we
assessed its level in pseudogout, an acute inﬂammatory condition
involving joint damage. Brieﬂy, human synovial ﬂuid samples
(n ¼ 382) were aspirated without lavage from a cross-sectional
convenience cohort with informed consent and approval of the
Lund University research ethics committee. Diagnosis was made by
arthroscopy, radiography, assessment of joint ﬂuid and clinical
examination. Diagnostic groups were knee-healthy references with
no history of joint injury or joint pain (n ¼ 10); pseudogout
(pyrophosphate crystal arthritis, n ¼ 34); joint injury sustained
between less than 1 week and 20 years before sample acquisition
(knee ACL rupture, with or without concomitant meniscus lesions,
n ¼ 136) or isolated knee meniscus injury (n ¼ 118); and knee OA
(n ¼ 84). Patients with pseudogout had radiographic OA corre-
sponding to Kellgren and Lawrence grade 1e3, whereas patientswith OA had radiographic OA corresponding to grade 2 or greater.
Patients with joint injury generally showed mild to moderate
cartilage damage on arthroscopic examination, with a few addi-
tionally having radiographic signs of OA corresponding to Kellgren
and Lawrence grade 1 or 2. The samples of this cohort were partly
identical with those used in previous studies16e19.
Cohort 4: matched human OA plasma and synovial ﬂuid samples
To better understand the relationship between synovial ﬂuid
and plasma NT in OA, we obtained matched plasma and synovial
ﬂuid samples from male and female knee OA patients (n ¼ 40;
n ¼ 20 per gender) just prior to knee replacement surgery from
Clinomics BioSciences Inc. (Pittsﬁeld, MA, USA). In addition, age-
and gender-matched control samples (n ¼ 40) were purchased
from Clinomics BioSciences, Inc.
Cohort 5: RA plasma samples
Plasma was collected from RA patients (n ¼ 18) before and after
treatment with anti-tumor necrosis factor (TNF) biotherapeutics
(etanercept, inﬂiximab, or adalimumab) over a 6-month period.
Control plasma samples (n ¼ 21) from an age-matched cohort of
healthy volunteers were obtained from PrecisionMed (San Diego,
CA, USA).
Disease activity score (DAS) of 28 joints
The disease activity score of 28 joints using C-reactive protein
(DAS28-3 CRP) was the outcomemeasure used as an indicator of RA
disease activity and response to treatment. It is the basis for several
other RA measurement tools and is widely used as an indicator of
RA disease activity and response to treatment20.
3-NT and NOx assays
We used a newly described assay for total NT (protein-con-
taining and protein-free) to measure NT levels in biological ﬂuids
(plasma, synovial ﬂuid and urine)21. Brieﬂy, quantiﬁcation of NT
from the human body ﬂuid samples was performed using immu-
noafﬁnity two-dimensional (2D) liquid chromatographyetandem
mass spectrometry (LCeMS/MS) using an HP 1100 HPLC system
(Agilent Technologies, Palo Alto, CA, USA) and a switching valve
(Valco Instruments, Houston, TX, USA) plumbed in-line with
a pump and interfaced to an API 4000 mass spectrometer (Applied
Biosystems/MDS-Sciex, Toronto, Canada) operated in the negative
ion electrospray and multiple reaction monitoring modes.
NOx was measured using a ﬂuorescent assay as previously
described22.
Immunoassays for MMPs, cytokines, chemokines, aggrecan
fragments, aggrecan epitope 846 and cartilage oligomeric matrix
protein (COMP)
MMP-1, MMP-3 and MMP-9 were measured in plasma from
patients with RA using a multiplex sandwich-based enzyme-linked
immunosorbent assay (ELISA) format (Meso Scale Discovery, Gai-
thersburg, MD, USA). Typically, a 5e10-fold dilution of biological
ﬂuid was analyzed. For measurement of cytokines and chemokines,
approximately 25 ml of each sample was analyzed for 42 different
human antigens as deﬁned in the manufacturer’s protocol (HCYTO-
80K-42PMCX; Millipore, Billerica, MA, USA): epidermal growth
factor (EGF), eotaxin, ﬁbroblast growth factor (FGF-2), ﬂt3 ligand
(Ftl3L), fractalkine, granulocyte colony-stimulating factor (G-CSF),
granulocyte/macrophage colony-stimulating factor (GM-CSF),
Table I
Relationship of SF NT and NOx to biomarkers of joint destruction and repair
SF ARGS SF COMP SF MMP-3 SF MMP-1 SF 846 SF CTx2B4
SF NT
correlation
coefﬁcient
0.286 0.052 0.241 0.252 0.081 0.437
P-value <0.001 0.655 <0.001 0.008 0.43 <0.001
n 87 75 190 109 98 174
SF NOx
correlation
coefﬁcient
0.012 0.149 0.022 0.015 0.005 0.061
P-value 0.904 0.16 0.752 0.869 0.957 0.39
n 100 90 216 127 113 199
846, 846 epitope of aggrecan; ARGS, ARGS-neoepitope generated by aggrecanase
cleavage of aggrecan interglobular domain; CTx2B4, type II cross-linked C-telo-
peptide 2B4 epitope; SF, synovial ﬂuid.
Variable number of assay results available due to limitations in SF sample volume.
T.P. Misko et al. / Osteoarthritis and Cartilage 21 (2013) 151e156 153growth-regulated oncogene (GRO), interferon alpha-2 (IFNa2),
interferon gamma (IFNg), interleukin (IL)-1a, IL-1b, IL-1 receptor
antagonist (ra), IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12
p40, IL-12 p70, IL-13, IL-15, IL-17, IFNg inducible protein 10 (IP-10),
monocyte chemoattractant protein (MCP)-1, MCP-3, macrophage-
derived chemokine (MDC), macrophage-inﬂammatory protein
(MIP)-1a, MIP-1b, soluble CD40 ligand (sCD40L), soluble IL-2
receptor a (sIL-2Ra), transforming growth factor a (TGFa), TNFa,
TNFb, vascular endothelial growth factor (VEGF), platelet-derived
growth factor a a (PDGF-AA), PDGF-AB/BB, and regulated upon
activation, normal T-cell expressed and secreted (RANTES). Only
those antigens showing a change with treatment are reported here.
Biomarker immunoassay results for a part of the synovial ﬂuid
samples of Cohort 3 were from published reports16e19. Assay
methodologies for aggrecan ARGS-neoepitope, aggrecan epitope
846, COMP, MMP-1, MMP-3 and cross-linked type II collagen C-
telopeptides (CTX-II) were as described16e19. CRP was measured
using a nephelometric immunoassay.
Statistical analysis
Data were analyzed using GraphPad Prism 4.0 (GraphPad Soft-
ware Inc., San Diego, CA, USA) and Sigmaplot 12.3 to assess normal
distribution of values and to calculate mean values, standard
deviations, conﬁdence intervals (CIs) and statistical signiﬁcance.
Either an unpaired Student’s t test with P value <0.05 or a one-way
analysis of variance (ANOVA), followed by the HolmeSidak or
Bonferroni test for multiple comparisons of datasets, was used to
determine level of signiﬁcance betweenmean values. If values werePl
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Fig. 1. (A) Plasma levels of NT in patients with OA (n ¼ 143) compared with controls
(n ¼ 174), urinary NT levels in OA (n ¼ 20) and controls (n ¼ 20). (B) Synovial ﬂuid (SF)
NT values (one-way ANOVA of log10-transformed data, followed by the Bonferroni
multiple comparisons test) in patients with OA (n ¼ 115), joint injury (ACL and/or
meniscus injury) (n ¼ 206) and pseudogout (n ¼ 31) compared with non-arthritic
controls (n ¼ 46). Values for SF nitrate/nitrite (NOx) from controls (n ¼ 50), patients
with OA (n ¼ 125), joint injury (n ¼ 254) and pseudogout (n ¼ 34). Bars show mean
values with 95% CIs.not normally distributed, log-transformed values were analyzed.
The Spearman rank correlation coefﬁcient was used to examine the
relationship between two potential markers for disease activity
using two-tailed P values of <0.05 as criteria for statistical
signiﬁcance.
A regression analysis was performed using the data derived
from the RA study. Besides plasma NT values, the demographic
variables of age, gender, alcohol consumption, smoking history and
hormonal status (pre- or post-menopausal) were included in the
analysis.
Results
Comparison of plasma and synovial ﬂuid NT levels in all healthy
volunteers and all patients with OA showed that plasma NT was
signiﬁcantly elevated in the OA group (P < 0.001; [Fig. 1(A)]). In the
subset of patients with OA evaluated in Cohort 2, urinary NT did not
show a statistically signiﬁcant difference versus controls for this
cohort [Fig. 1(A)]: 104.6 ng/mg creatinine (95% CI 69.6, 139.7) versus
104.1 ng/mg creatinine (95% CI 78.5, 129.6), respectively, despite
higher plasma levels of NT [704.1 pg/ml (95% CI 626.8, 781.4), versus
536.4 pg/ml (95% CI 454.7, 618.2)] for controls.
We found a statistically signiﬁcant elevation of synovial ﬂuid NT
in the OA, joint injury and pseudogout groups when comparedwith
the control group (P < 0.001; [Fig. 1(B)]). In these joint ﬂuid
samples, concentrations of NT were signiﬁcantly correlated with
levels of ARGS-aggrecan neoepitope generated by aggrecanase
cleavage of aggrecan (P  0.001), cross-linked C-telopeptides of
type II collagen (P < 0.001), and with protein levels of MMP-1
(P ¼ 0.008) and MMP-3 (P  0.001; Table I). In contrast, no statis-
tically signiﬁcant correlations were found between NT and COMPControl OA Control  OA
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Fig. 2. NT ratios for matched SF and plasma samples (late-stage OA patients at the time
of joint replacement, Clinomics BioSciences Inc., Pittsﬁeld, MA, USA) for the OA group
(n ¼ 40) compared with non-OA controls (n ¼ 37). NOx ratios for OA patients (n ¼ 40)
and controls (n ¼ 40). Bars show mean values with 95% CIs.
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Fig. 3. Plasma levels of NT from RA (n ¼ 18) were compared with healthy volunteer
(HV) controls (n ¼ 21) and to plasma levels following 3 and 6 months of anti-TNF
therapy (n ¼ 17). Values were analyzed using one-way ANOVA, followed by Bonferroni
multiple comparisons test. Bars show mean values with 95% CIs.
Table III
Correlation between key plasma markers of disease activity prior to initiation of
anti-TNFa therapy in patients with RA (n ¼ 18)
Biomarker Correlation with Spearman coefﬁcient P value
NT CRP 0.6549 0.0032
MMP-3 0.5934 0.0094
IP-10 0.4915 0.0383
MMP-1 0.4138 0.0878
DAS28-3 CRP sCD40L 0.4716 0.0482
MMP-9 0.5501 0.0180
EGF 0.4964 0.0361
sCD40L IP-10 0.7434 0.0004
EGF 0.5769 0.0122
MMP-3 MMP-1 0.4923 0.0380
CRP 0.5304 0.0236
MMP-1 MCP-1 0.5170 0.0280
MMP-9 IL-1b 0.5173 0.0279
TNFa 0.4770 0.0453
VEGF 0.4801 0.0437
GM-CSF 0.5480 0.0186
MIP-1b 0.5516 0.0176
IL-2 0.6969 0.0013
IL-10 0.5608 0.0155
DAS28-3 CRP, disease activity score measured by 28 tender and swollen joint counts
and C-reactive protein levels; IP-10, IFNg-induced protein 10.
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any of the other biomarkers (P  0.16).
In a smaller group of patients with OA prior to knee replacement
surgery and controls, the synovial ﬂuid to plasma NT ratio was
higher for the OA group when compared with the control group
(P ¼ 0.0047; Fig. 2) despite no statistically signiﬁcant increase in
synovial ﬂuid NOx in patients with OA [57.1 mM (95% CI 45.5, 68.7)
versus 56.2 mM (95% CI 45.2, 67.2) for controls, P¼ 0.9112]. Although
OA plasma NOx showed an apparent elevation [30.4 mM (95% CI
24.5, 36.3)] versus controls [23.0 mM (95% CI 19.5, 26.6); P¼ 0.0346],
the synovial ﬂuid to plasma NOx ratio was not statistically different
between the OA and control groups (Fig. 2; P ¼ 0.8837).
Patients with RA showed increased levels of plasma NT when
compared with healthy controls (P < 0.001; Fig. 3, Table II). Inter-
estingly, a decrease in plasma NT (P < 0.05) was observed after
6 months of anti-TNF therapy but not after 3 months of treatment
(Fig. 3, Table II). Compared with NT, the temporal modulation of
MMP-3 and MMP-1 levels was more rapid and corresponded more
closely to the pattern observed for both CRP and IL-6, both of which
were reduced by 3 months of treatment. As expected, DAS28-3 CRP
was also decreased by the anti-TNF treatment (Table II).
Before the initiation of anti-TNF therapy, we observed a corre-
lation between plasma NT and plasma levels of MMP-1 and MMP-3
(Table III). In addition to a strong correlation between plasma NT
and CRP (Table III), we found a strong correlation between
percentage change in log10 NT and the percentage change in the
log10 DAS28-3 CRP score when adjusted for age, alcoholTable II
RA plasma biomarkers that responded to anti-TNF therapy
Clinical score/biomarker,
mean (95% CI)
Baseline 3 months
DAS28-3 CRP 6.12 (5.79, 6.46) 4.05 (3.
P-value <0.001
IL-6 (pg/ml) 151.3 (101.6, 200.9) 74.8 (32
P-value <0.005
MMP-3 (ng/ml) 71.9 (20.1, 123.7) 22.1 (12
P-value 0.008
MMP-1 (ng/ml) 38.2 (23.5, 52.8) 15.6 (12
P-value <0.001
NT (pg/ml) 3774 (2711, 4838) 2955 (23
P-value 0.111
IP-10 (pg/ml) 352.8 (192.4, 513.2) 316.5 (14
P-value 0.503
CRP (mg/ml) 33.16 (18.0, 48.3) 9.41 (6.
P-value <0.001
Plasma was analyzed from RA patients (n ¼ 18) before and after anti-TNF treatment, a
each group and compared to the baseline (pre-treatment group) using one-way ANO
log10-transformed data for IL-6, MMP-3, MMP-1, NT, IP-10 and CRP.
IP-10, IFNg-induced protein 10; ND, not determined.consumption, and gender after 6months of anti-TNF therapy (Fig. 4,
Table IV). At 26 weeks of treatment, changes in NT level were
predictive of changes in DAS28-3 CRP scores when age, gender,
alcohol consumption and all second- and third-level interactions
were included (Fig. 4, Table IV).Discussion
A genuine need exists for clinical biomarkers for joint damage
and disease progression in arthritis. Using a novel assay for the
quantiﬁcation of NT, we demonstrated increased levels of NT in
synovial ﬂuid from patients with OA, joint injury, and pseudogout
versus controls. NT was also elevated in plasma from patients with
OA and RA compared with healthy controls. In RA, our results
demonstrate for the ﬁrst time that anti-TNF therapy decreased
plasma NT. This decrease in plasma NT correlated with markers of
RA disease activity, including MMP-1, MMP-3, CRP and DAS28-3
CRP. This is the ﬁrst time that a biomarker of oxidative/nitrative
damage like NT has been shown to correlate strongly with a clinical
disease activity tool like DAS28-3 CRP.6 months Healthy volunteers
58, 4.53) 3.74 (3.28, 4.19) ND
<0.001
.4, 117.3) 73.7 (30.2, 117.2) 0.75 (0.75, 0.75)
<0.001 <0.001
.0, 32.2) 15.5 (9.82, 21.1) 10.1 (7.50, 12.7)
0.002 <0.001
.2, 19.0) 14.2 (10.6, 17.7) 6.6 (4.23, 8.88)
<0.001 <0.001
54, 3556) 2374 (2014, 2734) 1257 (1105, 1410)
0.006 <0.001
7.3, 485.7) 131.9 (90.7, 173.2) 217.4 (166, 269)
0.014 0.672
68, 12.1) 7.79 (5.70, 9.90) ND
<0.001
nd from healthy volunteers (n ¼ 21). Mean and 95% CI values were calculated for
VA, followed by HolmeSidak multiple comparison. Signiﬁcance was assessed for
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Fig. 4. Relationship between the predicted percentage change in log10 disease activity
scores measured by 28 tender and swollen joint counts and C-reactive protein levels
(DAS28-3 CRP) and the observed percentage change in log10 DAS28-3 CRP clinical score
after 6 months of anti-TNF therapy.
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monocytes and a reduction in iNOS levels following anti-TNF
therapy23,24. However, NO reacts in a diffusion-limited manner
with superoxide anion to form peroxynitrite, a powerful oxidant
that has been linked to tissue injury. Because NT is a stable end
product of peroxynitrite formation, it should better reﬂect disease-
associated tissue injury than iNOS levels. The apparent delay in
plasma NT reduction, relative to other markers and DAS28-3 CRP,
may be explained by alternative pathways of iNOS regulation or by
the possibility that plasma NT is amarker for chronic tissue damage
rather than an acute response marker for inﬂammation like CRP or
MMPs. A further possible explanation for the delayed plasma NT
reduction is provided by our previous observation in a rodent study
that the clearance of nitrated proteins was slower than that of NOx
or free NT25. Disease-associated markers like rheumatoid factor
may well be among these nitrated proteins.
In order to evaluate the utility of NT as a biomarker for arthritis
and joint injury, we measured NT levels in urine, plasma and
synovial ﬂuid. We found that of the biological ﬂuids we examined
for NT, plasma and synovial ﬂuid displayed the most consistent
elevation in levels of this potential biomarker for disease activity.
Moreover, NT in these ﬂuids correlated well with previously
established markers for joint damage. Surprisingly, we did not
observe a similar pattern for urinary NT. Thus, we analyzed NT in
synovial ﬂuid, which should directly reﬂect the underlying
molecular processes affecting joint integrity, and also NT in plasma,
which should contain NT generated from the joint as well as from
other sources.Table IV
Parameters for model predicting percentage change in log10 DAS28-3 CRP (6-month
time point)
Parameter Parameter
estimate
P value Adjusted
R2 value
Intercept 29.612 0.653 0.871
Hormone status 16.015 0.034
Age 0.078 0.948
Gender 24.487 0.717
Age  gender 0.814 0.514
Alcohol 8.864 0.019
Age  alcohol 0.136 0.034
Gender  alcohol 12.962 0.014
Age  gender  alcohol 0.246 0.011
Percentage change log NT 1.131 0.014
DAS28-3 CRP, disease activity score measured by 28 tender and swollen joint counts
and C-reactive protein levels.We chose to compare our results with NOx (nitrite and nitrate)
because we had found NOx to be a more robust signal in biological
ﬂuids than nitrite alone and because peroxynitrite preferentially
breaks down into nitrate (greater than 90%of theNOx signal) if it fails
to oxidize surrounding molecular targets like protein, lipids and
nucleic acids1,26. With that said, in this study we did not observe
a correlation betweenNOx (usually predominantly nitrate inplasma)
and NT when measured in the same sample (data not shown).
Our present study demonstrated elevated synovial ﬂuid and
plasma levels of NT in OA, RA, joint injury and pseudogout. The lack
of any appreciable difference in synovial ﬂuid NOx in all samples,
including controls, reveals NT to be a better biomarker for joint
damage than NOx in these same ﬂuids. Importantly, synovial ﬂuid
NT (but not NOx) was correlatedwith synovial ﬂuidmarkers of joint
tissue degradation (ARGS-aggrecan, CTX-II, MMP-1, MMP-3), but
not with synovial ﬂuid COMP and aggrecan epitope 846, which
have been suggested to reﬂect joint tissue synthesis and repair27.
Similar to our results in OA, NT in plasma from patients with RA
correlated well with plasma markers of disease and joint destruc-
tion including CRP, IP-10 and MMP-3, all of which are increased in
RA and may contribute to joint pathophysiology28.
In summary, we have shown NT, but not NOx, to be increased in
synovial ﬂuid and plasma from patients with arthritis and joint
injury. The synovial ﬂuid to plasma ratio of NTwas greater than one
in OA patients, suggesting local joint production of NT, a marker for
peroxynitrite, the powerful oxidant generated by the reaction of NO
with superoxide. Furthermore, plasma NT was increased in RA
patients, responded to anti-TNF treatment, and was predictive of
changes in DAS28-3 CRP following treatment. Although further
studies are warranted in larger, prospective patient cohorts, our
results suggest that NT in synovial ﬂuid and plasma may serve as
a biomarker for joint destruction and that it may be used tomonitor
therapeutic efﬁcacy of disease-modifying treatment. Thus, the
identiﬁcation of NT as a potential biomarker may enable better
selection and stratiﬁcation of individuals with active joint disease
andmay help provide amore effective assessment of their response
to disease-modifying therapeutics.
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